1. Home
  2. DMAC vs ALCO Comparison

DMAC vs ALCO Comparison

Compare DMAC & ALCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DMAC
  • ALCO
  • Stock Information
  • Founded
  • DMAC 2000
  • ALCO 1960
  • Country
  • DMAC United States
  • ALCO United States
  • Employees
  • DMAC N/A
  • ALCO N/A
  • Industry
  • DMAC Biotechnology: Pharmaceutical Preparations
  • ALCO
  • Sector
  • DMAC Health Care
  • ALCO
  • Exchange
  • DMAC Nasdaq
  • ALCO Nasdaq
  • Market Cap
  • DMAC 310.1M
  • ALCO 257.5M
  • IPO Year
  • DMAC N/A
  • ALCO N/A
  • Fundamental
  • Price
  • DMAC $6.96
  • ALCO $33.53
  • Analyst Decision
  • DMAC Strong Buy
  • ALCO
  • Analyst Count
  • DMAC 3
  • ALCO 0
  • Target Price
  • DMAC $12.33
  • ALCO N/A
  • AVG Volume (30 Days)
  • DMAC 343.5K
  • ALCO 21.3K
  • Earning Date
  • DMAC 11-12-2025
  • ALCO 08-12-2025
  • Dividend Yield
  • DMAC N/A
  • ALCO 0.60%
  • EPS Growth
  • DMAC N/A
  • ALCO N/A
  • EPS
  • DMAC N/A
  • ALCO N/A
  • Revenue
  • DMAC N/A
  • ALCO $44,199,000.00
  • Revenue This Year
  • DMAC N/A
  • ALCO N/A
  • Revenue Next Year
  • DMAC N/A
  • ALCO N/A
  • P/E Ratio
  • DMAC N/A
  • ALCO N/A
  • Revenue Growth
  • DMAC N/A
  • ALCO N/A
  • 52 Week Low
  • DMAC $3.19
  • ALCO $24.23
  • 52 Week High
  • DMAC $7.49
  • ALCO $35.01
  • Technical
  • Relative Strength Index (RSI)
  • DMAC 58.60
  • ALCO N/A
  • Support Level
  • DMAC $6.75
  • ALCO N/A
  • Resistance Level
  • DMAC $7.13
  • ALCO N/A
  • Average True Range (ATR)
  • DMAC 0.28
  • ALCO 0.00
  • MACD
  • DMAC -0.06
  • ALCO 0.00
  • Stochastic Oscillator
  • DMAC 50.00
  • ALCO 0.00

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

About ALCO Alico Inc.

Alico Inc is a Florida-based agribusiness and land management company that primarily focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells primarily Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers most of the revenue as the firm's primary operating business unit.

Share on Social Networks: